Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2011-05-24
2011-05-24
Bristol, Lynn (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C435S007230, C514S171000
Reexamination Certificate
active
07947275
ABSTRACT:
Serum-containing and serum-free immunoglobulin inhibitors of steroid hormone responsive cancer cell growth are disclosed, along with their methods of production. Also disclosed are defined cell culture media, assay protocols, and model systems using the inhibitors for demonstrating steroid hormone growth effects of natural and synthetic substances, and other cell culture applications. The disclosed compositions and methods employing the immunoglobulin inhibitors are also useful as reagents in research, and for the diagnosis, treatment and prevention of mucus epithelial cancers.
REFERENCES:
patent: 4849508 (1989-07-01), Magnin et al.
patent: 4859585 (1989-08-01), Sonnenschein et al.
patent: 5075425 (1991-12-01), Kotitschke et al.
patent: 5135849 (1992-08-01), Soto et al.
patent: 5405772 (1995-04-01), Ponting
patent: 6200547 (2001-03-01), Volkonsky et al.
patent: 2002/0006630 (2002-01-01), Sirbasku
patent: 0702960 (1996-03-01), None
patent: WO 92/13563 (1992-08-01), None
patent: WO 91/16061 (1991-10-01), None
patent: WO 95/09011 (1995-04-01), None
patent: WO98/04681 (1998-02-01), None
patent: WO98/08934 (1998-03-01), None
patent: WO 00/06723 (2000-02-01), None
Yildirim (Tr. J. Med. Sci., 1998, 28:383-387.
Biology online definition of “steroid hormone” (pp. 1-2 ; Nov. 25, 2009).
MedicineNet.com definition of :thyroid hormone (pp. 1-2; Nov. 25, 2009).
ATCC website search for “MCF-K” (p. 1; Nov. 25, 2009).
ATCC website search for “MTW9/PL2” (p. 1; Nov. 25, 2009).
ATCC website search for“MCF-7A” (p. 1; Nov. 25, 2009).
ATCC website search for “H-301” (p. 1; Nov. 25, 2009).
Furuya et al (Cancer Research, Dec. 1989, vol. 49, pp. 6670-6674).
Hoffman (‘The Biochemistry of Clinical Medicine’, 1970, pp. 48 and 55).
Karmanos Cancer Center website search (“MCF-7”; Apr. 20, 2010; pp. 1-2).
Partial International Search in PCT/US 01/15183, Applicant David A. Sirbasku, International Filing Date Oct. 5, 2001, Date of Mailing Aug. 8, 2002, pp. 4.
Partial International Search in PCT/US 01/15171, Applicant David A. Sirbasku, International Filing Date Oct. 5, 2001, Date of Mailing Aug. 29, 2002, pp. 3.
JP Parisot et al., “Altered Expression of the IGF-1 Receptor in a Tamoxifen-Resistant Human Breast Cancer Cell Line,” British Journal of Cancer, vol. 79, No. 5-6, pp. 693-700, 1999.
David Danielpour et al., “Growth of MTW9/PL2 Estrogen-Responsive Rat Mammary Tumor Cells in Hormonally Defined Serum-Free Media,” In Vitro Cell. Dev. Biol., vol. 24, No. 1, pp. 42-52, Jan. 1988.
Research Diagnostics Inc., ′Online! Jan. 10, 2000, XP002207863, Retrieved from the Internet: <URL:http://www.researchd.com/rdiabs/igref.ser.htm> 'retrieved on Jul. 29, 2002! The whole document, p. 1.
Jorge E. Moreno-Cuevas et al., “Estrogen Mitogenic Action. I. Demonstration of Estrogen-Dependent MTW9/PL2 Carcinogen-Induced Rat Mammary Tumor Cell Growth in Serum-Supplemented Culture and Technical Implications,” In Vitro Cell. Dev. Biol.—Animal, vol. 36, No. 7, pp. 410-427, Jul.-Aug. 2000.
David A. Sirbasku et al., “Estrogen Mitogenic Action. II. Negative Regulation of the Steroid Hormone-Responsive Growth of Cell Lines Derived From Human and Rodent Target Tissue Tumors and Conceptual Implications,” In Vitro Cell. Dev. Biol.—Animal, vol. 36, No. 7, pp. 428-446, Jul.-Aug. 2000.
Helenice Gobbi et al., “Transforming Growth Factor-β and Breast Cancer Risk in Women With Mammary Epithelial Hyperplasia,” Journal of the National Cancer Institute, vol. 91, No. 24, pp. 2096-2101, Dec. 15, 1999.
Ruth Sager, “Expression Genetics in Cancer: Shifting the Focus from DNA to RNA,” Proc. Natl. Acad. Sci. USA, vol. 94, No. 3, pp. 952-955, Feb. 1997.
Sanford D. Markowitz et al., “Tumor Suppressor Activity of the TGF-β Pathway in Human Cancers,” Cytokine & Growth Factor Reviews, vol. 7, No. 1, pp. 99-102, 1996.
International Search Report, PCT/US02/36632 dated Jul. 28, 2003 (1 p.).
PCT International Search Report, PCT/US01/15183 dated 20/112002, 3 pages.
Zhihong Chen et al.,A serum-free medium for hybridoma cell culture, Cytotechnology (1993), vol. 11, pp. 169-174, XP001117870, ISSN: 0920-9069 p. 170, media and additives; pp. 173-174.
Database Biosis ′Online! Biosciences Information Service, Philadelphia, PA US; 1992, Eby J.E. et al.,Preparation of Iron-Deficient Tissue Culture Medium by Deferoxamine-Sepharose Treatment and Application to the Differential Actions of Apotransferrin and Difieric Transferrin, Database assession No. PREV199294057133, XP002218819 cited in the application abstract & Analytical Biochemistry, vol. 203, No. 2, 1992, pp. 317-325, ISSN:0003-2697.
Database Biosis ′Online! Biosciences Information Service, Philadelphia, PA US 1993, Eby John E. et al.,Apotransferrin stimulation of thyroid hormone dependent rat pituitary tumor cell growth in serum-free chemically defined medium: Role of iron(III)chelation, Database accession No. PREV199396113609, XP002218820 cited in application abstract & Journal of Cellular Physiology, vol. 156, No. 3, 1993, pp. 588-600, ISSN:0021-9541.
Neumannova Vera et al.,Growth of human tumor cell lines in transferrin-free, low-iron medium, In Vitro Cellular & Developmental Biology Animal, vol. 31, No. 8, 1995, pp. 625-632, XP001118629, ISSN:1071-2690, the whole document.
C.A. Janeway et al.,Chapter 3: Structure of the Antibody Molecule and the Immunoglobulin Genes: Structural variation in immunoglobulin constant regions; Chapter 9: The Humoral Immune Response: The distribution and functions of immunoglobulin isotypes, Immuno. Biology—The Immune System In Health and Disease, Fourth Edition, Elsevier Science Ltd./Garland Publishing (1999) pp. 104, 326-327.
R.G. Hamilton,Chapter 3: Human Immunoglobulins, Handbook of Human Immunology, CRC Press LLC (1997) pp. 65-109.
A.J. Alberg et at.,Epidemiology, prevention, and early detection of breast cancer [Breast], Current Opinion in Oncology (Nov. 1997) vol. 9, 6, pp. 505-511, PMID: 9370070 [PubMed—indexed for MEDLINE); Abstract http://www.ncbi.nlm.nih.gov/entrez/querv.fcgi?cmd=Retrieve&db=PubMed&list—uids=9370070&d... printed on Feb. 15, 2003 (1 page).
A.J. Alberg et al.,Epidemiology, prevention, and early detection of breast cancer [Breast], Current Opinion in Oncology (Nov. 1999) vol. 11, No. 6, pp. 435, 13 pages.
J.C. Allegra et al.,Growth of a Human Breast Cancer Cell Line in Serum-Free Hormone-Supplemented Medium, Cancer Research (Nov. 1978) vol. 38, pp. 3823-3829.
J.F. Amara et al.,17β-Estradiol Has A Biphasic Effect On GH Cell Growth, Endocrinology, Dept. of Pharm., Endocrinology (Mar. 1983) vol. 112, No. 3, pp. 1141-1143.
T. Anttila et al.,Serotypes of Chlamydia Trachomatis and Risk for Development of Cervical Squamous Cell Carcinoma, JAMA (Jan. 2001) vol. 285, No. 1, pp. 47-51, PMID: 11150108 [PubMed—indexed for MEDLINE); Abstract http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list—uids=11150108&d... printed on Feb. 15, 2003 (2 pages).
T. Anttila et al.,Serotypes of Chlamydia Trachomatis and Risk for Development of Cervical Squamous Cell Carcinoma, JAMA (Jan. 2001) vol. 285, No. 1, pp. 47-51, (Original Contribution) 11 pages.
J.M. Zenilman,Chlamydia and Cervical Cancer: A Real Association? JAMA (Jan. 2001) 285, No. 1, pp. 81-83, (Editorial) 5 pages.
P.E. Gravitt et al.,Chlamydia trachomatis and Cervical Squamous Cell Carcinoma, JAMA (Apr. 2001) vol. 285, No. 13, pp. 1703-1706, (Letters) 11 pages).
B.A. Arrick,Therapeutic implications of the TGF-beta system, J: Mammary Gland Biol. Neoplasia. (Oct. 1996) 1(4):391-7, PMID: 10887513 [PubMed—indexed for MEDLINE); Abstract http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list—uids=10887513&d... printed on Feb. 21, 2003 (1 page).
C.L. Arteaga et al.,Blockade of the Epidermal Growth Factor Receptor Inhibits Trans
Bristol Lynn
Signe Biopharma, Inc.
Woodard Emhardt Moriarty McNett & Henry LLP
LandOfFree
Compositions and methods for demonstrating secretory immune... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for demonstrating secretory immune..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for demonstrating secretory immune... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2661490